Ocular Therapeutix (OCUL) Long-Term Debt Issuances (2013 - 2023)
Ocular Therapeutix (OCUL) posted quarterly Long-Term Debt Issuances of $2.1 million for Q2 2021, little changed on a QoQ basis from $2.1 million in Q1 2021.
Ocular Therapeutix (OCUL) Long-Term Debt Issuances (2013 - 2023) Analysis & Trends
Ocular Therapeutix has reported Long-Term Debt Issuances for 6 years, with the latest figure at $2.1 million in Q2 2021.
- Long-Term Debt Issuances for Q2 2021 came in at $2.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $2.1 million (changed N/A YoY), and the FY2023 annual result was $82.5 million, changed N/A from the prior year.
- Long-Term Debt Issuances was little changed at $2.1 million in Q2 2021, from $2.1 million in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $37.3 million in Q1 2019 and troughed at -$70000.0 in Q2 2019.
- A 4-year average of $6.4 million and a median of $2.1 million in 2021 frame the typical range for Long-Term Debt Issuances.
- The largest YoY upside for Long-Term Debt Issuances was 3529.25% in 2019 against a maximum downside of 104.54% in 2019.
- A 4-year view of Long-Term Debt Issuances shows it stood at $3.7 million in 2017, then jumped by 114.0% to $7.9 million in 2018, then plunged by 100.88% to -$70000.0 in 2019, then soared by 3077.14% to $2.1 million in 2021.
- Per Business Quant data, the three most recent Long-Term Debt Issuances figures were $2.1 million in Q2 2021, $2.1 million in Q1 2021, and -$70000.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -80.47 Mn |
| Dec 31, 2023 | -80.47 Mn |
| Jun 30, 2021 | 2.08 Mn |
| Jun 30, 2021 | 2.08 Mn |
| Mar 31, 2021 | 2.08 Mn |
| Mar 31, 2021 | 2.08 Mn |
| Jun 30, 2019 | -70,000.00 |
| Jun 30, 2019 | -70,000.00 |
| Mar 31, 2019 | 37.35 Mn |
| Mar 31, 2019 | 37.35 Mn |
| Dec 31, 2018 | 7.92 Mn |
| Dec 31, 2018 | 7.92 Mn |
| Sep 30, 2018 | 1.54 Mn |
| Sep 30, 2018 | 1.54 Mn |
| Jun 30, 2018 | 1.54 Mn |
| Jun 30, 2018 | 1.54 Mn |
| Mar 31, 2018 | 1.03 Mn |
| Mar 31, 2018 | 1.03 Mn |
| Dec 31, 2017 | -2.40 Mn |
| Dec 31, 2017 | -2.40 Mn |